B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Monday, setting a price target of $138, which is approximately 23.20% above the present share price of $112.01.
Mamtani expects Arcturus Therapeutics to post earnings per share (EPS) of -$0.92 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Arcturus Therapeutics, with an average price target of $92.71.
The analysts price targets range from a high of $140 to a low of $65.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.33 million and a net profit of -$20.94 million. The company's market cap is $2.74 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 32.0% and a 53.11% success rate.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.